Panbela therapeutics announces $5.0 million bought deal offering of common stock

Minneapolis, june 29, 2021 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla) (the “company” or “panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it has entered into an underwriting agreement with h.c. wainwright & co., llc under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the company at a price to the public of $3.00 per share, less underwriting discounts and commissions. the closing of the public offering is expected to occur on or about july 2, 2021, subject to satisfaction of customary closing conditions.
PBLA Ratings Summary
PBLA Quant Ranking